ID1 and rheumatoid arthritis: We have demonstrated that an autologous and spatial‐hindrance‐based Ab lock34 can efficiently prevent interference from anti‐Adalimumab Id Ab, thus maintaining the PK properties similar to the original drug and reducing the RA progression in the presence of anti‐Adalimumab Id Abs.